Geisinger Health System Hits Milestone with 150,000 Participants in Biobank and DNA Sequencing Study

Geisinger Health System Hits Milestone with 150,000 Participants in Biobank and DNA Sequencing Study
Geisinger Health System announced that 150,000 participants have signed up for its comprehensive biobank and DNA sequencing study, known as the “MyCode Community Health Initiative.” The U.S. Centers for Disease Control and Prevention estimates that nearly 2 million people in the U.S. are at an increased risk for adverse health outcomes because they have genetic mutations that predispose them to one of the following conditions: hereditary breast and ovarian cancer syndrome, Lynch syndrome, and hereditary high cholesterol. These are three conditions among a total of 27 that Geisinger informs MyCode participants about as a result of the nation’s largest genomic sequencing study. MyCode analyzes the DNA of patient participants to help improve healthcare delivery. The study aims to find ways to diagnose certain conditions earlier and to develop new treatments or management strategies. The goal is to give every Geisinger patient the opportunity to participate in the study. “This is an important milestone for us and it’s only the beginning,” David H. Ledbetter, PhD, Geisinger executive vice president and chief scientific officer, said in a press release. “Each and every new participant allows us to perform research that will help us find new ways to anticipate or identify sometimes life-threatening medical conditions early and greatly improve health outcomes.” MyCode was launched in January 2014 in collaboration with the Regeneron Genetics Center. The program originally set out to recruit 100,000 study participants over five years. Due to overwhelming patient response, that goal has been increased to 250,000. The growing database from the MyCode project will help to better inform and benefit current and future research, as well as provid
Subscribe or to access all post and page content.